EUVIMEDEUVIMED entdecken
Crossref

Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer

Lianqi Zhao, Tingting Li, Yinwei Zhou, Pengbo Wang, Lin Luo

International Immunopharmacology · 2024-12 · 143 · 113395

DOI: 10.1016/j.intimp.2024.113395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Lianqi Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, PR China; Ouyue Biotech. Inc, Suzhou, Jiangsu 215400, PR China; In Vivo Pharmacology…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mice, Inbred BALB C, Antigens, CD. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1), an extensively studied cell surface molecule, mainly expressed by certain epithelial, endothelial, lymphoid and myeloid cells, and is an attractive target for cancer immunotherapy. Here, to investigate the anti-tumor effects and mechanisms of CEACAM1 antibody, we prepared the antibody and explored its anti-tumor effects on Non-small Cell Lung Cancer (NSCLC) in vitro and in vivo. Firstly, antigen of human CEACAM1 recombinant protein was immunized on BALB/c mice and the high-affinity mouse anti-human monoclonal antibody 3C11 was selected by hybridoma technique. Next, ELISA was applied to detect the blocking effects of 3C11 on CEACAM1-CEACAM1 and CEACAM1-CEACAM5. Then, cell assays and ELISA were used to evaluate the role of 3C11 in blocking CEACAM1-CEACAM1 immunosuppressive signal transduction between dendritic cells (DCs) and T cells or natural killer cells (NK) and tumor cells. Finally, the synergistic anti-tumor effect of 3C11 combined with anti-PD-1 antibody was evaluated through cell stimulation assays and NCI-H358-induced tumor models in mice. The results showed the EC50 of 3C11 binding to NCI-H358 or exhausted T cells were 0.04971 μg/mL and 0.03475 μg/mL, respectively. 3C11 activated the exhausted T cells and enhanced the killing effect of NK by blocking CEACAM1-CEACAM1. In addition, the combination of 3C11 and anti-PD1 antibody produced synergistic anti-tumor effect on NSCLC. Its improved tumor growth inhibition value (TGI) of anti-PD-1 from 18 % to 85 % in vivo. These findings suggest that 3C11 can be considered an effective immunotherapy drug for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMice, Inbred BALB CAntigens, CDAntibodies, MonoclonalImmunotherapyCell Adhesion MoleculesProgrammed Cell Death 1 ReceptorAnimalsHumansMiceCell Line, TumorKiller Cells, NaturalFemaleImmune Checkpoint InhibitorsDendritic CellsT-LymphocytesXenograft Model Antitumor AssaysCarcinoembryonic Antigen

Stichwörter der Autor:innen

CEACAM1Exhausted T cellNKNon-small cell lung cancerTargeting the IgV domain

Substanzen

Antigens, CDCD66 antigensAntibodies, MonoclonalCell Adhesion MoleculesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCarcinoembryonic AntigenPDCD1 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, PR China; Ouyue Biotech. Inc, Suzhou, Jiangsu 215400, PR China; In Vivo Pharmacology, Frontage Laboratories, Suzhou, Jiangsu 215400, PR China.
  • School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, PR China; Ouyue Biotech. Inc, Suzhou, Jiangsu 215400, PR China.
  • School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, PR China.
  • Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR China. Electronic address: pengbow611@163.com.
  • School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, PR China. Electronic address: luolin@ntu.edu.cn.

Zitieren

APA

Zhao, L., Li, T., Zhou, Y., Wang, P., & Luo, L. (2024). Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer. International Immunopharmacology, 143, 113395. https://doi.org/10.1016/j.intimp.2024.113395

Vancouver

Zhao L, Li T, Zhou Y, Wang P, Luo L. Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer. International Immunopharmacology. 2024;143:113395. doi:10.1016/j.intimp.2024.113395

BibTeX
@article{Zhao2024,
  author = {Zhao, Lianqi and Li, Tingting and Zhou, Yinwei and Wang, Pengbo and Luo, Lin},
  title = {Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113395},
  doi = {10.1016/j.intimp.2024.113395}
}
Kostenlos starten →